(NASDAQ: NKTX) Nkarta's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Nkarta's earnings in 2026 is -$99,933,000.On average, 8 Wall Street analysts forecast NKTX's earnings for 2026 to be -$112,240,358, with the lowest NKTX earnings forecast at -$117,091,133, and the highest NKTX earnings forecast at -$105,171,676. On average, 8 Wall Street analysts forecast NKTX's earnings for 2027 to be -$115,595,835, with the lowest NKTX earnings forecast at -$136,723,179, and the highest NKTX earnings forecast at -$104,420,450.
In 2028, NKTX is forecast to generate -$104,542,077 in earnings, with the lowest earnings forecast at -$107,275,110 and the highest earnings forecast at -$99,913,092.